Could a sweetener beat a gut infection? early trial tests xylitol for c. diff in IBD patients
NCT ID NCT06799039
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This pilot study tests whether xylitol, a common sugar alcohol, can safely clear C. difficile bacteria from the guts of people with inflammatory bowel disease (IBD). About 69 adults with mild or inactive IBD will take different doses of xylitol for up to 8 weeks. Researchers will check for side effects, whether the infection clears, and if IBD symptoms improve.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
xylitol (a sugar alcohol)
What this could lead to
If it works, this could point toward a simple, low-cost way to clear C. difficile infections in people with IBD, potentially reducing flare-ups and need for stronger drugs.
What could go wrong
This is a very early, small pilot trial (69 people) testing multiple doses for safety first. It may not show clear benefit, and xylitol might cause digestive side effects or fail to clear the infection.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INFLAMMATORY BOWEL DISEASE (IBD) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-••••
Locations
-
Brigham and Women's Hospital
Boston, Massachusetts, 02115, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••